Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.
FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad
Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.
A more general warning encourages consumers to engage in a personal discussion with their doctor about a drug, and it promotes engagement with longer-format printed or digitally-delivered information.
Nielsen data shows pharma spent $4.5 billion on DTC ads last year.
FDA posted a revised draft guidance document on its brief summary and adequate directions for use concerning risk information in DTC print ads to reflect "recent social science research."
The FDA is looking into whether abbreviated risk information is a good idea for DTC.
Patient advocates lobbied the FDA to approve the MS drug and Sanofi subsidiary Genzyme says their voice will be part of the consumer outreach when DTC rolls out next year.
Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.
Stream Health, WPP's "unconference" which took place in Florida earlier this week, provided a diverse and large amount of content in a short amount of time.
Healthcare workers seek out health-related information on their own time, and through internet connections other than ones offered by their employers.
The media company has added managed-markets expertise to its roster, bringing on the former head of IMS Health's global payer/provider division.
Parent company CVS Caremark is changing its name to better reflect "its broader health care commitment."
Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma company to pair with the Crohn's and Colitis Foundation of America.
The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.
Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.
Influential patients are reaching critical mass. What can't they do?
A study indicates consumers stop using them at the six-month mark.
Arena's recent quarter shows weight-loss drug Belviq is on the rise. It follows a DTC push and the recent addition of reps by co-marketer Eisai.
The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.
The company refutes a Financial Times rumor that one was happening soonish.
NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."
He started the Dose of Digital blog in 2008, then left healthcare. Now, after more than two years away, Jonathan Richman says he's back in the business.
The FDA says the OTC remedy maker's online behavior—including Liking customer Facebook posts—has put the company's drugs in unapproved drug territory.
The drugmaker received a notice from the advertising watchdog over promotion of hep. B treatment Viread in a sponsored link on Google AdWords.
Patients want to do more with mobile and see doctors less. Two studies outline the types of digital interventions patients are interested in.
The consumer-facing edition of The Merck Manual Go-To Home Guide for Symptoms is being released as a mobile app.
Researchers from Boston Children's Hospital, Harvard Medical School and Brigham and Women's Hospital are offering a bit of internet advice for the Food and Drug Administration: do more.
The networking site's emotion experiment rankles some in the science and political communities.
A US Pharma juror's—and silver Lions Health winner's—opinion on why the Americans didn't fare well in Cannes, and tips for improvement
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.